Thomas, M., Thatcher, N., & Goldschmidt, J. (2019). Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy, 11(15), . https://doi.org/10.2217/imt-2019-0125
Chicago-Zitierstil (17. Ausg.)Thomas, Michael, Nicholas Thatcher, und Jerome Goldschmidt. "Totality of Evidence in the Development of ABP 215, an Approved Bevacizumab Biosimilar." Immunotherapy 11, no. 15 (2019). https://doi.org/10.2217/imt-2019-0125.
MLA-Zitierstil (9. Ausg.)Thomas, Michael, et al. "Totality of Evidence in the Development of ABP 215, an Approved Bevacizumab Biosimilar." Immunotherapy, vol. 11, no. 15, 2019, https://doi.org/10.2217/imt-2019-0125.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.